Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 248 of the 249 references it cites were found in a registry or an index.
Abstract
In vivo exploration of activated microglia in neurodegenerative diseases is achievable by Positron Emission Tomography (PET) imaging, using dedicated radiopharmaceuticals targeting the translocator protein-18 kDa (TSPO). In this review, we emphasized the major advances made over the last 20 years, thanks to TSPO PET imaging, to define the pathophysiological implication of microglia activation and neuroinflammation in neurodegenerative diseases, including Parkinson’s disease, Huntington’s disease, dementia, amyotrophic lateral sclerosis, multiple sclerosis, and also in psychiatric disorders. The extent and upregulation of TSPO as a molecular biomarker of activated microglia in the human brain is now widely documented in these pathologies, but its significance, and especially its protective or deleterious action regarding the disease’s stage, remains under debate. Thus, we exposed new and plausible suggestions to enhance the contribution of TSPO PET imaging for biomedical research by exploring microglia’s role and interactions with other cells in brain parenchyma. Multiplex approaches, associating TSPO PET radiopharmaceuticals with other biomarkers (PET imaging of cellular metabolism, neurotransmission or abnormal protein aggregates, but also other imaging modalities, and peripheral cytokine levels measurement and/or metabolomics analysis) was considered. Finally, the actual clinical impact of TSPO PET imaging as a routine biomarker of neuroinflammation was put into perspective regarding the current development of diagnostic and therapeutic strategies for neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The translocator protein, a hallmark of activated microglia, serves as the gold standard for PET-based neuroinflammation imaging [57].”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [57]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Methods to image microglia exist and are being used to test the effect of treatments on microglia205–210.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [206]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Diagnostic and Statistical Manual of Mental Disorders(DSM)
(2008) · Encyclopedia of Counseling · doi:10.4135/9781412963978.n182 · Cited by 10,830
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“MCI represents a diagnostic entity for the transition between normal aging and AD dementia [113].”
BackgroundPolazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366 · cited 1×
“HD is neuropathologically characterized by the formation of intranuclear inclusions of mHTT [81] resulting in striatal, cortical and hypothalamic atrophy [82,83] which are associated with an accumulation of reactive microglia in these same regions [31,84].”
BackgroundResting microglial cells are highly dynamic surveillants of brain parenchyma in vivo
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827 · cited 1×
“Several cellular actors including neurons, astrocytes, T-cells and the blood brain barrier (BBB) modulate microglial function and form a very dynamic network [5].”
BackgroundJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 1×
“, amoeboid, rod, multi-nucleated, epithelioid or dystrophic state) and functional changes of microglia, known as microglial “activation” [6,9].”
BackgroundMicroglia: Active sensor and versatile effector cells in the normal and pathologic brain
Hanisch, U.-K., & Kettenmann, H. (2007) · Nature Neuroscience · doi:10.1038/nn1997 · Cited by 3,676 · cited 3×
“, PAMPS and/or DAMPS) which is integrated in a time-dependent fashion (acute versus chronic injury) [6].”
BackgroundAGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 1×
“In line with these ex vivo findings, TSPO PET imaging showed higher microglial activation in various cortical regions known to be the seat of Aβ deposits [124] (e.”
ResultNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · cited 1×
“Unlike NFTs, amyloid plaques deposition showed a lesser stereotypical spatiotemporal pattern of progression; they accumulate mainly in the isocortex, and the amyloid burden does not correlate with the severity or the duration of dementia [117,118].”
BackgroundBraak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
(2013) · The Lancet · doi:10.1016/s0140-6736(12)62129-1 · Cited by 3,010
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990 · cited 1×
“Since the discovery of activated microglia in a post mortem study of PD brains, objectified by a large amount of HLA-DR-positive microglial cells in the locus niger, “neuroinflammation” became one of the main culprits in the pathogenesis and in the progression of PD [48].”
BackgroundKiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538 · cited 1×
“In addition to parkinsonism, the clinical features of PSP include early falls and abnormal eye movements (vertical supranuclear gaze palsy) [70].”
BackgroundLichtenstein, P., Yip, B. H., Björk, C., Pawitan, Y., Cannon, T. D., Sullivan, P. F., & Hultman, C. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60072-6 · Cited by 2,125
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 1×
“Unlike NFTs, amyloid plaques deposition showed a lesser stereotypical spatiotemporal pattern of progression; they accumulate mainly in the isocortex, and the amyloid burden does not correlate with the severity or the duration of dementia [117,118].”
BackgroundMicroglial physiology: unique stimuli, specialized responses
Ransohoff, R. M., & Perry, V. H. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132528 · Cited by 1,858 · cited 1×
“The brain homeostasis is achieved in part though the ability of microglia to regulate inflammation, such as cytotoxicity, repair and regeneration [3].”
BackgroundNeuroinflammation and M2 Microglia: The Good, the Bad, and the Inflamed
Cherry, J. D., Olschowka, J. A., & O’Banion, M. K. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-98 · Cited by 1,748 · cited 1×
“Aβ (both, soluble [120] and fibrillary [121]) can bind to several Toll-like receptors (TLR) and co-receptors expressed on microglia, leading to its activation [122] and promoting the formation of clusters of activated microglia surrounding amyloid plaques in AD brains [123].”
BackgroundGlobal burden of depressive disorders in the year 2000
Üstün, T. B., Ayuso-Mateos, J. L., Chatterji, S., Mathers, C., & Murray, C. J. L. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.5.386 · Cited by 1,735
Neuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Magliozzi, R., Howell, O., Vora, A., Serafini, B., Nicholas, R., Puopolo, M., Reynolds, R., & Aloisi, F. (2006) · Brain · doi:10.1093/brain/awm038 · Cited by 1,443
Papadopoulos, V., Baraldi, M., Guilarte, T. R., Knudsen, T. B., Lacapère, J.-J., Lindemann, P., Norenberg, M. D., Nutt, D., Weizman, A., Zhang, M.-R., et al. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.06.005 · Cited by 1,389 · cited 1×
“It has been renamed as 18-kDa translocator protein (TSPO) to better reflect the cellular functions and tissue distribution of this protein [14].”
BackgroundRole of pro-inflammatory cytokines released from microglia in Alzheimer's disease.
(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.03.49 · Cited by 1,288 · cited 1×
“This Aβ-induced inflammatory environment [126], combined with effect of immunosenescence on microglia [127,128], lead to a situation in which microglia that initially exhibited a neuroprotective M2 phenotype at the beginning of AD [129], become confined to a classical activated state (i.”
BackgroundSpecific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding
Braestrup, C., & Squires, R. F. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.9.3805 · Cited by 1,264 · cited 1×
“This secondary binding site for diazepam, which is distinct in its structure from the CBR, was shown to be abundantly distributed in peripheral tissues [13].”
BackgroundIn vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · cited 6×
“No significant change in 11C-PK11195 binding Gerhard et al. (2006) [51] MSA/PSP 7 MSA and 4 PSP patients vs. 7 HC 11C-PK11195 Increased tracer binding in putamen, thalamus, midbrain, frontal and deep white matter Kobylecki et al. (2013) [61] CBD 4 CBD patients vs. HC 11C-PK11195 Significantly…”
BackgroundResultInfluentialRole of Pro-Inflammatory Cytokines Released from Microglia in Neurodegenerative Diseases
Smith, J. A., Das, A., Ray, S. K., & Banik, N. L. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.10.004 · Cited by 1,165
The subgenual anterior cingulate cortex in mood disorders
Drevets, W. C., Savitz, J., & Trimble, M. (2008) · CNS Spectrums · doi:10.1017/s1092852900013754 · Cited by 1,109
In-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054 · cited 1×
“, prefrontal [104,107,108], temporal [100–102,104–109,125], occipital [101,104,105,107,108,125], precuneus [101,109,110], cingulum [100,104,110]) in AD dementia patients, compared to healthy subjects.”
BackgroundHuntington disease: natural history, biomarkers and prospects for therapeutics
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016 · cited 2×
“to lesion topology, which even depends on the stage of HD, symptoms include motor troubles (chorea, parkinsonism), cognitive decline (slowed mentation, impaired strategy) and psychiatric disorders (mood, irritability, apathy, depression) [77,90].”
BackgroundSetiawan, E., Wilson, A. A., Mizrahi, R., Rusjan, P. M., Miler, L., Rajkowska, G., Suridjan, I., Kennedy, J. L., Rekkas, P. V., Houle, S., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2427 · Cited by 939
Review: Activation patterns of microglia and their identification in the human brain
Boche, D., Perry, V. H., & Nicoll, J. A. R. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12011 · Cited by 912 · cited 1×
“When macrophages release TGF-β or IL-10 (M2c reaction), anti-inflammatory effects are observed [7,11].”
BackgroundMeningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Howell, O. W., Reeves, C. A., Nicholas, R., Carassiti, D., Radotra, B., Gentleman, S. M., Serafini, B., Aloisi, F., Roncaroli, F., Magliozzi, R., et al. (2011) · Brain · doi:10.1093/brain/awr182 · Cited by 858
Hauw, J.-J., Daniel, S. E., Dickson, D., Horoupian, D. S., Jellinger, K., Lantos, P. L., McKee, A., Tabaton, M., & Litvan, I. (1994) · Neurology · doi:10.1212/wnl.44.11.2015 · Cited by 852 · cited 1×
“The hallmark of PSP comprises the deposition of 4-repeat (4R) tau protein in neurofibrillary tangles and neuropil threads that are found in the basal ganglia and brainstem [71].”
BackgroundMicroglial activation and dopamine terminal loss in early Parkinson's disease
Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005) · Annals of Neurology · doi:10.1002/ana.20338 · Cited by 843 · cited 3×
“…10 HC 11C-PK11195 Midbrain tracer BPND in PD group greater than in the healthy volunteers No significant difference in thalamus or striatum binding Ouchi et al. (2005) [49] - 18 PD patients with a wide range of disease severity vs. 11 HC - 8 PD patients with a longitudinal follow-up (PET after…”
BackgroundBrain atrophy in Alzheimer’s Disease and aging
Pini, L., Pievani, M., Bocchetta, M., Altomare, D., Bosco, P., Cavedo, E., Galluzzi, S., Marizzoni, M., & Frisoni, G. B. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.002 · Cited by 836
Steiner, J., Bielau, H., Brisch, R., Danos, P., Ullrich, O., Mawrin, C., Bernstein, H.-G., & Bogerts, B. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.10.013 · Cited by 791
A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis
Magliozzi, R., Howell, O. W., Reeves, C., Roncaroli, F., Nicholas, R., Serafini, B., Aloisi, F., & Reynolds, R. (2010) · Annals of Neurology · doi:10.1002/ana.22230 · Cited by 747
Turner, M. R., Cagnin, A., Turkheimer, F. E., Miller, C. C. J., Shaw, C. E., Brooks, D. J., Leigh, P. N., & Banati, R. B. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.012 · Cited by 737 · cited 12×
“Moreover, “microgliopathy”, assessed by CD68- and Iba1-reactive microglial cells, correlated with the disease progression and is linked to the severity of upper motor neuron deficits in the corticospinal tract of ALS patient autopsies [149].”
BackgroundInfluentialNeuroinflammation: The role and consequences
Lyman, M., Lloyd, D. G., Ji, X., Vizcaychipi, M. P., & Ma, D. (2014) · Neuroscience Research · doi:10.1016/j.neures.2013.10.004 · Cited by 730 · cited 1×
“, IL-6 release [97]) and may support microglial activation [98], highlighting the vicious circle of”
BackgroundOffice of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration
Dickson, D. W., Bergeron, C., Chin, S. S., Duyckaerts, C., Horoupian, D., Ikeda, K., Jellinger, K., Lantos, P. L., Lippa, C. F., Mirra, S. S., et al. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.11.935 · Cited by 724 · cited 5×
“No significant change in 11C-PK11195 binding Gerhard et al. (2006) [51] MSA/PSP 7 MSA and 4 PSP patients vs. 7 HC 11C-PK11195 Increased tracer binding in putamen, thalamus, midbrain, frontal and deep white matter Kobylecki et al. (2013) [61] CBD 4 CBD patients vs. HC 11C-PK11195 Significantly increased tracer BPND in…”
BackgroundInfluentialPrevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis
Boeschoten, R. E., Braamse, A. M. J., Beekman, A. T. F., Cuijpers, P., van Oppen, P., Dekker, J., & Uitdehaag, B. M. J. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.11.067 · Cited by 713
Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis
McMahon, E. J., Bailey, S. L., Castenada, C. V., Waldner, H., & Miller, S. D. (2005) · Nature Medicine · doi:10.1038/nm1202 · Cited by 694
Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley–Whyte, E. T., Frosch, M. P., Albert, M. S., Hyman, B. T., & Irizarry, M. C. (2004) · Neurology · doi:10.1212/01.wnl.0000115115.98960.37 · Cited by 666
The peripheral benzodiazepine binding site in the brain in multiple sclerosis
Banati, R. B., Newcombe, J., Gunn, R. N., Cagnin, A., Turkheimer, F., Heppner, F., Price, G., Wegner, F., Giovannoni, G., Miller, D. H., et al. (2000) · Brain · doi:10.1093/brain/123.11.2321 · Cited by 661
Identification of Genetic Factors that Modify Clinical Onset of Huntington’s Disease
Lee, J.-M., Wheeler, V. C., Chao, M. J., Vonsattel, J. P. G., Pinto, R. M., Lucente, D., Abu-Elneel, K., Ramos, E. M., Mysore, J. S., Gillis, T., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.003 · Cited by 655
Björkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., Raibon, E., Lee, R. V., Benn, C. L., Soulet, D., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080178 · Cited by 650 · cited 1×
“This mutation in the exon 1 of the gene encoding the Huntingtin protein (HTT) leads to a mutant HTT (mHTT) which is expressed by peripheral monocytes of premanifest HD patients [78], and induces both a loss of function (e.”
BackgroundBrooks, D. J., Ibanez, V., Sawle, G. V., Quinn, N., Lees, A. J., Mathias, C. J., Bannister, R., Marsden, C. D., & Frackowiak, R. S. J. (1990) · Annals of Neurology · doi:10.1002/ana.410280412 · Cited by 626
Neocortical glial cell numbers in human brains
Pelvig, D. P., Pakkenberg, H., Stark, A. K., & Pakkenberg, B. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.013 · Cited by 601 · cited 1×
“Microglia represent approximately 5–15% of all cells in the human brain [1,2].”
Backgroundvan Berckel, B. N., Bossong, M. G., Boellaard, R., Kloet, R., Schuitemaker, A., Caspers, E., Luurtsema, G., Windhorst, A. D., Cahn, W., Lammertsma, A. A., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.025 · Cited by 582
Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study
Doorduin, J., de Vries, E. F. J., Willemsen, A. T. M., de Groot, J. C., Dierckx, R. A., & Klein, H. C. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.066647 · Cited by 559
Early and Progressive Accumulation of Reactive Microglia in the Huntington Disease Brain
Sapp, E., Kegel, K. B., Aronin, N., Hashikawa, T., Uchiyama, Y., Tohyama, K., Bhide, P. G., Vonsattel, J. P., & Difiglia, M. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.2.161 · Cited by 540 · cited 2×
“Furthermore, in manifest HD patients, the correlation between striatal TSPO tracer binding and the severity of motor symptoms (evaluated by the unified Huntington’s disease rating scale) [85,88] could echo the ex vivo relationship found between neuronal loss and density of reactive microglia [84].”
BackgroundMitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease
Ryan, B. J., Hoek, S., Fon, E. A., & Wade-Martins, R. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.02.003 · Cited by 524 · cited 1×
“Subsequently, this ROS generation leads to an accumulation of defective mitochondria due to an ineffective mitophagy PARK2-dependent mitochondriopathy [24], which is involved in several neurodegenerative diseases such as Parkinson’s disease (PD) [25], Huntington’s disease (HD) [26] and Alzheimer‘s disease (AD) [27].”
BackgroundHamelin, L., Lagarde, J., Dorothée, G., Leroy, C., Labit, M., Comley, R. A., de Souza, L. C., Corne, H., Dauphinot, L., Bertoux, M., et al. (2016) · Brain · doi:10.1093/brain/aww017 · Cited by 519 · cited 4×
“Longitudinal studies exhibited an increase in cortical-activated microglia during the course of AD [101,103,110].”
BackgroundInfluentialThe Indispensable Roles of Microglia and Astrocytes during Brain Development
Reemst, K., Noctor, S. C., Lucassen, P. J., & Hol, E. M. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00566 · Cited by 516 · cited 1×
“In parallel to their well-known immune-modulatory functions, microglia are highly dynamic cells which contribute to the synaptic remodelling/plasticity as well as synaptogenesis, synaptic transmission and pruning [4].”
BackgroundEdison, P., Archer, H. A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F. E., Hammers, A., Tai, Y. F., Fox, N., Kennedy, A., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.08.001 · Cited by 513 · cited 2×
“, prefrontal [104,107,108], temporal [100–102,104–109,125], occipital [101,104,105,107,108,125], precuneus [101,109,110], cingulum [100,104,110]) in AD dementia patients, compared to healthy subjects.”
BackgroundMorales, I., Guzmán-MartÃnez, L., Cerda-Troncoso, C., FarÃas, G. A., & Maccioni, R. B. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00112 · Cited by 490 · cited 1×
“, IL-6 release [97]) and may support microglial activation [98], highlighting the vicious circle of”
BackgroundBitsch, A., Bruhn, H., Vougioukas, V. I., Stringaris, A. K., Lassmann, H., Frahm, J., & Brück, W. (1999) · Research Portal (King's College London) · Cited by 468
Microglial activation correlates with severity in Huntington disease: A clinical and PET study
Pavese, N., Gerhard, A., Tai, Y. F., Ho, A. K., Turkheimer, F., Barker, R. A., Brooks, D. J., & Piccini, P. (2006) · Neurology · doi:10.1212/01.wnl.0000222734.56412.17 · Cited by 462 · cited 1×
“Furthermore, in manifest HD patients, the correlation between striatal TSPO tracer binding and the severity of motor symptoms (evaluated by the unified Huntington’s disease rating scale) [85,88] could echo the ex vivo relationship found between neuronal loss and density of reactive microglia [84].”
BackgroundNeuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
Jellinger, K. A. (2012) · Movement Disorders · doi:10.1002/mds.23795 · Cited by 451 · cited 1×
“Given the fact that a chronological spread of LB inclusions occurred in α-synucleinopathies [57], and these α-synuclein can directly provoke microglial activation [58], we could expect to find, in a time-dependent fashion, a widespread TSPO signal in PET imaging.”
BackgroundBloomfield, P. S., Selvaraj, S., Veronese, M., Rizzo, G., Bertoldo, A., Owen, D. R., Bloomfield, M. A. P., Bonoldi, I., Kalk, N., Turkheimer, F., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14101358 · Cited by 443
Microglial activation in presymptomatic Huntington's disease gene carriers
Tai, Y. F., Pavese, N., Gerhard, A., Tabrizi, S. J., Barker, R. A., Brooks, D. J., & Piccini, P. (2007) · Brain · doi:10.1093/brain/awm044 · Cited by 440 · cited 1×
“Moreover, striatal 11C-PK11195 binding is strongly correlated with the five-year probability of disease onset in asymptomatic HD gene carriers [86,88].”
BackgroundGhetti, B., Oblak, A. L., Boeve, B. F., Johnson, K. A., Dickerson, B. C., & Goedert, M. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12213 · Cited by 438
Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS
Liao, B., Zhao, W., Beers, D. R., Henkel, J. S., & Appel, S. H. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.06.011 · Cited by 438
Visualising microglial activation in vivo
Banati, R. B. (2002) · Glia · doi:10.1002/glia.10144 · Cited by 428 · cited 1×
“TSPO is widely distributed in most peripheral organs including kidneys, nasal epithelium, adrenal glands, lungs and heart, whilst the highest concentrations are in the steroid producing tissues; is also minimally expressed in resting microglial cells in the healthy brain [15].”
BackgroundNuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers
Chauveau, F., Boutin, H., Van Camp, N., Dollé, F., & Tavitian, B. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0908-9 · Cited by 417 · cited 1×
“However, 11C-(R)-PK11195 clinical usefulness is narrowed by several major limitations, including the short half-life of carbon-11, a low brain bioavailability and a poor signal-to-noise ratio due to high nonspecific binding [37].”
BackgroundVarnum, M. M., & Ikezu, T. (2012) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0181-2 · Cited by 394 · cited 3×
“, M1) with strongly reduced Aβ-clearing capabilities in the advanced stage of AD [7].”
BackgroundJimenez, S., Baglietto-Vargas, D., Caballero, C., Moreno-Gonzalez, I., Torres, M., Sanchez-Varo, R., Ruano, D., Vizuete, M., Gutierrez, A., & Vitorica, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3024-08.2008 · Cited by 383 · cited 1×
“This Aβ-induced inflammatory environment [126], combined with effect of immunosenescence on microglia [127,128], lead to a situation in which microglia that initially exhibited a neuroprotective M2 phenotype at the beginning of AD [129], become confined to a classical activated state (i.”
BackgroundMackenzie, I. R. A., & Neumann, M. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13588 · Cited by 381
Microglial activation and amyloid deposition in mild cognitive impairment: A PET study
Okello, A., Edison, P., Archer, H. A., Turkheimer, F. E., Kennedy, J., Bullock, R., Walker, Z., Kennedy, A., Fox, N., Rossor, M., et al. (2009) · Neurology · doi:10.1212/01.wnl.0000338622.27876.0d · Cited by 367 · cited 1×
“Analogous to Aβ and tau that has already accumulated in the brain of MCI patients [114], PET imaging showed that microglial activation occurred before the onset of clinical symptoms of dementia [108,110,115].”
BackgroundAn [18F]dopa–PET and clinical study of the rate of progression in Parkinson’s disease
Morrish, P. K., Sawle, G. V., & Brooks, D. J. (1996) · Brain · doi:10.1093/brain/119.2.585 · Cited by 366
Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review
Trépanier, M. O., Hopperton, K. E., Mizrahi, R., Mechawar, N., & Bazinet, R. P. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.90 · Cited by 360
Reactive Astrocytes Overexpress TSPO and Are Detected by TSPO Positron Emission Tomography Imaging
Lavisse, S., Guillermier, M., Hérard, A.-S., Petit, F., Delahaye, M., Van Camp, N., Ben Haim, L., Lebon, V., Remy, P., Dollé, F., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1487-12.2012 · Cited by 359 · cited 1×
“showed that reactive astrocytes could also overexpress TSPO using a model of selective astrocyte activation in the rat striatum [17].”
MethodHaider, L., Simeonidou, C., Steinberger, G., Hametner, S., Grigoriadis, N., Deretzi, G., Kovacs, G. G., Kutzelnigg, A., Lassmann, H., & Frischer, J. M. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307712 · Cited by 357
In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease
Kreisl, W. C., Lyoo, C. H., McGwier, M., Snow, J., Jenko, K. J., Kimura, N., Corona, W., Morse, C. L., Zoghbi, S. S., Pike, V. W., et al. (2013) · Brain · doi:10.1093/brain/awt145 · Cited by 350 · cited 5×
“Comparison in TSPO density between mild cognitive impairment due to AD (MCI) and AD dementia yielded ambiguous results: significant difference was found between the two groups [101,102,109] or was absent [110–112] according to different studies.”
BackgroundResultInfluentialBeumer, W., Gibney, S. M., Drexhage, R. C., Pont-Lezica, L., Doorduin, J., Klein, H. C., Steiner, J., Connor, T. J., Harkin, A., Versnel, M. A., et al. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0212100 · Cited by 347
Le Fur, G., Perrier, M. L., Vaucher, N., Imbault, F., Flamier, A., Benavides, J., Uzan, A., Renault, C., Dubroeucq, M. C., & Guérémy, C. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90062-0 · Cited by 345 · cited 1×
“Then, the most widely used TSPO PET radiopharmaceutical, namely 11C-(R)-PK11195, an isoquinoline carboxamide developed in the early 1980s, was the first non-benzodiazepine type compound identified to bind to TSPO with high affinity (human Kd = 2 nM) [36].”
MethodDeficiency of Inducible Nitric Oxide Synthase Protects Against MPTP Toxicity In Vivo
Dehmer, T., Lindenau, J., Haid, S., Dichgans, J., & Schulz, J. B. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0742213.x · Cited by 337
Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors
Crotti, A., Benner, C., Kerman, B. E., Gosselin, D., Lagier-Tourenne, C., Zuccato, C., Cattaneo, E., Gage, F. H., Cleveland, D. W., & Glass, C. K. (2014) · Nature Neuroscience · doi:10.1038/nn.3668 · Cited by 333 · cited 1×
“, abnormal protein-protein interaction, promoting pro-inflammatory cytokines) [79,80].”
Evidence for activation of microglia in patients with psychiatric illnesses
Bayer, T. A., Buslei, R., Havas, L., & Falkai, P. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00545-5 · Cited by 323
Neuroplastic changes in depression: A role for the immune system
Eyre, H., & Baune, B. T. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.03.019 · Cited by 319
Harris, J. A., Devidze, N., Verret, L., Ho, K., Halabisky, B., Thwin, M. T., Kim, D., Hamto, P., Lo, I., Yu, G.-Q., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.020 · Cited by 319 · cited 1×
“A transcellular propagation of abnormal tau proteins [93] and Aβ [94] occurred in AD.”
BackgroundMicroglial Dysregulation in Psychiatric Disease
Frick, L. R., Williams, K., & Pittenger, C. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/608654 · Cited by 299
Interferon-Induced Depression in Chronic Hepatitis C: A Systematic Review and Meta-Analysis
Udina, M., Castellví, P., Moreno-España, J., Navinés, R., Valdés, M., Forns, X., Langohr, K., Solà, R., Vieta, E., & Martín-Santos, R. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r07694 · Cited by 297
Vowinckel, E., Reutens, D., Becher, B., Verge, G., Evans, A., Owens, T., & Antel, J. P. (1997) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19971015)50:2<345::aid-jnr22>3.0.co;2-5 · Cited by 297
The Role of Genetics in the Etiology of Schizophrenia
Gejman, P. V., Sanders, A. R., & Duan, J. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.12.003 · Cited by 296
Ferrante, R. J., Kowall, N. W., Beal, M. F., Martin, J. B., Bird, E. D., & Richardson, E. P. (1987) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-198701000-00002 · Cited by 294 · cited 1×
“HD is neuropathologically characterized by the formation of intranuclear inclusions of mHTT [81] resulting in striatal, cortical and hypothalamic atrophy [82,83] which are associated with an accumulation of reactive microglia in these same regions [31,84].”
BackgroundMicroglia actions in Alzheimer's disease
Prokop, S., Miller, K. R., & Heppner, F. L. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1182-x · Cited by 291 · cited 1×
“Aβ (both, soluble [120] and fibrillary [121]) can bind to several Toll-like receptors (TLR) and co-receptors expressed on microglia, leading to its activation [122] and promoting the formation of clusters of activated microglia surrounding amyloid plaques in AD brains [123].”
Backgrounddos Santos Picanco, L. C., Ozela, P. F., de Fatima de Brito Brito, M., Pinheiro, A. A., Padilha, E. C., Braga, F. S., de Paula da Silva, C. H. T., dos Santos, C. B. R., Rosa, J. M. C., & da Silva Hage-Melim, L. I. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867323666161213101126 · Cited by 284
Maezawa, I., Zimin, P. I., Wulff, H., & Jin, L.-W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.135244 · Cited by 278 · cited 1×
“Aβ (both, soluble [120] and fibrillary [121]) can bind to several Toll-like receptors (TLR) and co-receptors expressed on microglia, leading to its activation [122] and promoting the formation of clusters of activated microglia surrounding amyloid plaques in AD brains [123].”
BackgroundAP-HP, H. D. L. P.-S., & Gordon, P. (2013) · Aging and Disease · doi:10.14336/ad.2013.0400295 · Cited by 277
Microglia, Amyloid, and Glucose Metabolism in Parkinson’s Disease with and without Dementia
Edison, P., Ahmed, I., Fan, Z., Hinz, R., Gelosa, G., Ray Chaudhuri, K., Walker, Z., Turkheimer, F. E., & Brooks, D. J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.255 · Cited by 274 · cited 3×
“…al. (2013) [61] 8 PD patients without dementia vs. 10 HC 11C-PK11195 BPND significant increase in temporal, parietal and occipital cortical regions Edison et al. (2013) [52] 19 PD patients vs. 17 HC 18F-FEPPA No significant difference in striatal VT values between PD patients and controls…”
BackgroundParkin-mediated mitophagy in mutant hAPP neurons and Alzheimer's disease patient brains
Ye, X., Sun, X., Starovoytov, V., & Cai, Q. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv056 · Cited by 274 · cited 1×
“Subsequently, this ROS generation leads to an accumulation of defective mitochondria due to an ineffective mitophagy PARK2-dependent mitochondriopathy [24], which is involved in several neurodegenerative diseases such as Parkinson’s disease (PD) [25], Huntington’s disease (HD) [26] and Alzheimer‘s disease (AD) [27].”
BackgroundBrettschneider, J., Toledo, J. B., Van Deerlin, V. M., Elman, L., McCluskey, L., Lee, V. M.-Y., & Trojanowski, J. Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039216 · Cited by 268
Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine
Irwin, D. J., Cairns, N. J., Grossman, M., McMillan, C. T., Lee, E. B., Van Deerlin, V. M., Lee, V. M.-Y., & Trojanowski, J. Q. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1380-1 · Cited by 264
Mitochondrial benzodiazepine receptors regulate steroid biosynthesis.
Mukhin, A. G., Papadopoulos, V, Costa, E., & Krueger, K. E. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.9813 · Cited by 256 · cited 1×
“TSPO is thought to be involved in a wide array of vital cellular functions including porphyrin transport and heme synthesis, regulation of cell proliferation, steroid biosynthesis and programmed cell death [21].”
BackgroundDoorn, K. J., Moors, T., Drukarch, B., van de Berg, W. D., Lucassen, P. J., & van Dam, A.-M. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0090-1 · Cited by 254 · cited 1×
“Moreover, identified by positive CD68 immunoreactivity, amoeboid activated microglial cells were identified in both the striatum and the hippocampus of PD patients, suggesting that an inflammatory response occurs to the active α-synuclein pathology in the hippocampus area [53].”
BackgroundDavies, D. S., Ma, J., Jegathees, T., & Goldsbury, C. (2017) · Brain Pathology · doi:10.1111/bpa.12456 · Cited by 251 · cited 2×
“On the basis of that postulate, we hypothesize that the profound morphological deterioration of microglial cells which occurred in AD [128] could be a source of signal variability in TSPO PET imaging.”
BackgroundMolecular Imaging of Microglial Activation in Amyotrophic Lateral Sclerosis
Corcia, P., Tauber, C., Vercoullie, J., Arlicot, N., Prunier, C., Praline, J., Nicolas, G., Venel, Y., Hommet, C., Baulieu, J.-L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052941 · Cited by 249
Self-citation[ 11 C]( R )-PK11195 PET imaging of microglial activation in multiple system atrophy
Gerhard, A., Banati, R. B., Goerres, G. B., Cagnin, A., Myers, R., Gunn, R. N., Turkheimer, F., Good, C. D., Mathias, C. J., Quinn, N., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000078192.95645.e6 · Cited by 246 · cited 11×
“Remarkably, the analysis of histopathological patterns of MSA brains revealed that the amount of GCIs and the level of microglial activity is reduced especially since the tissue injury becomes severe in white matter areas, unlike gray matter areas [69].”
BackgroundInfluentialLyoo, C. H., Ikawa, M., Liow, J.-S., Zoghbi, S. S., Morse, C. L., Pike, V. W., Fujita, M., Innis, R. B., & Kreisl, W. C. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.146027 · Cited by 237 · cited 1×
“Comparison in TSPO density between mild cognitive impairment due to AD (MCI) and AD dementia yielded ambiguous results: significant difference was found between the two groups [101,102,109] or was absent [110–112] according to different studies.”
ResultBiological hypotheses and biomarkers of bipolar disorder
Sigitova, E., Fišar, Z., Hroudová, J., Cikánková, T., & Raboch, J. (2017) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12476 · Cited by 235 · cited 1×
“…of literature suggests that several pathophysiological processes may sequentially and/or concurrently occur in BD, as well as corticolimbic control circuits deterioration, monoaminergic neurotransmission imbalance or microglia homeostasis disruption (for review, see Sigitova et al., 2016 [154]).”
BackgroundThe microglial-motoneuron dialogue in ALS.
Appel, S. H., Zhao, W., Beers, D. R., & Henkel-Tigges, J. (2011) · PubMed Central · Cited by 230
PINK1-induced mitophagy promotes neuroprotection in Huntington’s disease
Khalil, B., El Fissi, N., Aouane, A., Cabirol-Pol, M.-J., Rival, T., & Liévens, J.-C. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.581 · Cited by 230 · cited 1×
“Subsequently, this ROS generation leads to an accumulation of defective mitochondria due to an ineffective mitophagy PARK2-dependent mitochondriopathy [24], which is involved in several neurodegenerative diseases such as Parkinson’s disease (PD) [25], Huntington’s disease (HD) [26] and Alzheimer‘s disease (AD) [27].”
BackgroundLe Fur, G., Guilloux, F., Rufat, P., Benavides, J., Uzan, A., Renault, C., Dubroeucq, M. C., & Guérémy, C. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90063-2 · Cited by 227
Zürcher, N. R., Loggia, M. L., Lawson, R., Chonde, D. B., Izquierdo-Garcia, D., Yasek, J. E., Akeju, O., Catana, C., Rosen, B. R., Cudkowicz, M. E., et al. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.01.009 · Cited by 226
Howell, O. W., Rundle, J. L., Garg, A., Komada, M., Brophy, P. J., & Reynolds, R. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181f3a5b1 · Cited by 222
Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease
Jucaite, A., Svenningsson, P., Rinne, J. O., Cselényi, Z., Varnäs, K., Johnström, P., Amini, N., Kirjavainen, A., Helin, S., Minkwitz, M., et al. (2015) · Brain · doi:10.1093/brain/awv184 · Cited by 222 · cited 2×
“…pathway, cortical regions, thalamus and cerebellum after 4 and 8 weeks of treatment No significant differences in changes of VT between the two arms Jucaite et al. (2015) [62] MSA 5 MSA patients vs. 6 HC 11C-PK11195 Increased tracer binding in dorsolateral prefrontal cortex, putamen, pallidum,…”
BackgroundMethodYasuno, F., Ota, M., Kosaka, J., Ito, H., Higuchi, M., Doronbekov, T. K., Nozaki, S., Fujimura, Y., Koeda, M., Asada, T., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.021 · Cited by 221 · cited 1×
“, prefrontal [104,107,108], temporal [100–102,104–109,125], occipital [101,104,105,107,108,125], precuneus [101,109,110], cingulum [100,104,110]) in AD dementia patients, compared to healthy subjects.”
BackgroundIannaccone, S., Cerami, C., Alessio, M., Garibotto, V., Panzacchi, A., Olivieri, S., Gelsomino, G., Moresco, R. M., & Perani, D. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.07.002 · Cited by 221 · cited 1×
“Furthermore, TSPO PET imaging shows that the microglial shift, from a sensing to a reactive state, takes place at the early stage of PD [49,54] and can occur even without dementia [52,55].”
BackgroundGelfand, J. M. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52001-2.00011-x · Cited by 220
Marinova‐Mutafchieva, L., Sadeghian, M., Broom, L., Davis, J. B., Medhurst, A. D., & Dexter, D. T. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06189.x · Cited by 217 · cited 1×
“This was corroborated by reported data from a rat model of PD, where the activation of microglia seems to precede dopaminergic neuronal cell loss [56].”
ResultStefanova, N., Reindl, M., Neumann, M., Kahle, P. J., Poewe, W., & Wenning, G. K. (2007) · Movement Disorders · doi:10.1002/mds.21671 · Cited by 217 · cited 1×
“Unlike the PD scenario progression, microglial activation in a mouse model of MSA-like neurodegeneration occurred parallel to the dopaminergic neuronal loss in the locus niger [68].”
BackgroundPET visualization of microglia in multiple sclerosis patients using [11C]PK11195
Debruyne, J. C., Versijpt, J., Van Laere, K. J., De Vos, F., Keppens, J., Strijckmans, K., Achten, E., Slegers, G., Dierckx, R. A., Korf, J., et al. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00571.x · Cited by 217
Fan, Z., Aman, Y., Ahmed, I., Chetelat, G., Landeau, B., Ray Chaudhuri, K., Brooks, D. J., & Edison, P. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.016 · Cited by 212 · cited 2×
“, prefrontal [104,107,108], temporal [100–102,104–109,125], occipital [101,104,105,107,108,125], precuneus [101,109,110], cingulum [100,104,110]) in AD dementia patients, compared to healthy subjects.”
BackgroundPolitis, M., Pavese, N., Tai, Y. F., Kiferle, L., Mason, S. L., Brooks, D. J., Tabrizi, S. J., Barker, R. A., & Piccini, P. (2011) · Human Brain Mapping · doi:10.1002/hbm.21008 · Cited by 212 · cited 5×
“To such an extent, microglial activation seems to begin in cognitive regions, especially in associative striatum and correlated with cognitive dysfunction [88].”
BackgroundResultInfluentialNeuroinflammation in bipolar disorder – A [11C]-(R)-PK11195 positron emission tomography study
Haarman, B. C. M. (., Riemersma-Van der Lek, R. F., de Groot, J. C., Ruhé, H. G. (., Klein, H. C., Zandstra, T. E., Burger, H., Schoevers, R. A., de Vries, E. F. J., Drexhage, H. A., et al. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.03.016 · Cited by 211
Ishizawa, K., & Dickson, D. W. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.6.647 · Cited by 209 · cited 6×
“No significant change in 11C-PK11195 binding Gerhard et al. (2006) [51] MSA/PSP 7 MSA and 4 PSP patients vs. 7 HC 11C-PK11195 Increased tracer binding in putamen, thalamus, midbrain, frontal and deep white matter Kobylecki et al. (2013) [61] CBD 4 CBD patients vs. HC 11C-PK11195 Significantly increased tracer BPND in…”
BackgroundInfluentialEvaluation of the PBR/TSPO Radioligand [ 18 F]DPA-714 in a Rat Model of Focal Cerebral Ischemia
Martín, A., Boisgard, R., Thézé, B., Van Camp, N., Kuhnast, B., Damont, A., Kassiou, M., Dollé, F., & Tavitian, B. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.205 · Cited by 206 · cited 1×
“Likewise, after brain injury induced by focal cerebral ischemia, both microglia and astrocytes have been found to overexpress TSPO [18], with a dissimilar distribution within the infarcted lesion.”
BackgroundHannestad, J., DellaGioia, N., Gallezot, J.-D., Lim, K., Nabulsi, N., Esterlis, I., Pittman, B., Lee, J.-Y., O’Connor, K. C., Pelletier, D., et al. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.06.010 · Cited by 204
Neuroinflammatory component of gray matter pathology in multiple sclerosis
Herranz, E., Giannì, C., Louapre, C., Treaba, C. A., Govindarajan, S. T., Ouellette, R., Loggia, M. L., Sloane, J. A., Madigan, N., Izquierdo‐Garcia, D., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24791 · Cited by 200
Ikawa, M., Lohith, T. G., Shrestha, S., Telu, S., Zoghbi, S. S., Castellano, S., Taliani, S., Da Settimo, F., Fujita, M., Pike, V. W., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178996 · Cited by 195 · cited 2×
“Nonetheless, the clinical relevance of these compounds remains to be confirmed [41].”
BackgroundImaging Microglial Activation with TSPO PET: Lighting Up Neurologic Diseases?
Vivash, L., & O’Brien, T. J. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.141713 · Cited by 190 · cited 1×
“A summary of the different generation of TSPO radiotracers from Vivash and O’Brien [43].”
BackgroundTranslational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia
Notter, T., Coughlin, J. M., Gschwind, T., Weber-Stadlbauer, U., Wang, Y., Kassiou, M., Vernon, A. C., Benke, D., Pomper, M. G., Sawa, A., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2016.248 · Cited by 190
Dodel, R., Spottke, A., Gerhard, A., Reuss, A., Reinecker, S., Schimke, N., Trenkwalder, C., Sixel‐Döring, F., Herting, B., Kamm, C., et al. (2010) · Movement Disorders · doi:10.1002/mds.22732 · Cited by 187 · cited 10×
“If we generalize this concept of microglial (down/up)-regulation according to lesion severity in MSA, that could explain that 11C-PK11195 binding increased in the thalamus or decreased in the substantia nigra after 24 weeks of active disease, compared to baseline [63].”
BackgroundMethodInfluentialIn vivo detection of microglial activation in frontotemporal dementia
Cagnin, A., Rossor, M., Sampson, E. L., MacKinnon, T., & Banati, R. B. (2004) · Annals of Neurology · doi:10.1002/ana.20332 · Cited by 187
Paola, M., Macaluso, E., Carlesimo, G. A., Tomaiuolo, F., Worsley, K. J., Fadda, L., & Caltagirone, C. (2007) · Journal of Neurology · doi:10.1007/s00415-006-0435-1 · Cited by 186
Henkel, J. S., Beers, D. R., Siklós, L., & Appel, S. H. (2006) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.10.016 · Cited by 181
VDAC activation by the 18 kDa translocator protein (TSPO), implications for apoptosis
Veenman, L., Shandalov, Y., & Gavish, M. (2008) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-008-9142-1 · Cited by 181 · cited 1×
“Most studies point out that high TSPO expression attenuates ROS generation [22,23].”
BackgroundBartels, A. L., Willemsen, A. T. M., Doorduin, J., de Vries, E. F. J., Dierckx, R. A., & Leenders, K. L. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2009.05.005 · Cited by 181 · cited 1×
“…unchanged Gerhard et al. (2006) [51] 14 PD patients vs. 8 HC 11C-PK11195 PD patients showed higher putamen and midbrain tracer BPND than controls Bartels et al. (2010) [60] 6 early-stage drug-naive PD patients vs. 11 HC 11C-PK11195 PD patients showed increased putamen and substantia nigra…”
BackgroundHypothalamic–endocrine aspects in Huntington's disease
Petersén, Å., & Björkqvist, M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04985.x · Cited by 177 · cited 1×
“HD is neuropathologically characterized by the formation of intranuclear inclusions of mHTT [81] resulting in striatal, cortical and hypothalamic atrophy [82,83] which are associated with an accumulation of reactive microglia in these same regions [31,84].”
BackgroundIncreased PK11195 PET binding in the cortex of patients with MS correlates with disability
Politis, M., Giannetti, P., Su, P., Turkheimer, F., Keihaninejad, S., Wu, K., Waldman, A., Malik, O., Matthews, P. M., Reynolds, R., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182635645 · Cited by 176
Takano, A., Arakawa, R., Ito, H., Tateno, A., Takahashi, H., Matsumoto, R., Okubo, Y., & Suhara, T. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000313 · Cited by 175
Yokokura, M., Mori, N., Yagi, S., Yoshikawa, E., Kikuchi, M., Yoshihara, Y., Wakuda, T., Sugihara, G., Takebayashi, K., Suda, S., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1612-0 · Cited by 174 · cited 1×
“In most studies, in parallel to cognitive deterioration, objectified by a decreased MMSE score [105,106,125] or increased CDR-SB [101,109], TSPO expression density in cortical regions was linearly raised.”
BackgroundHypothalamic involvement in Huntington's disease: an in vivo PET study
Politis, M., Pavese, N., Tai, Y. F., Tabrizi, S. J., Barker, R. A., & Piccini, P. (2008) · Brain · doi:10.1093/brain/awn244 · Cited by 174 · cited 1×
“In line with these findings, in vivo microglia PET imaging showed an overexpression of TSPO in the striatum [84–88] ,cortical regions [85,87–89] and hypothalamus [87,88] (Table 3).”
Result11C-PBR28 binding to translocator protein increases with progression of Alzheimer's disease
Kreisl, W. C., Lyoo, C. H., Liow, J.-S., Wei, M., Snow, J., Page, E., Jenko, K. J., Morse, C. L., Zoghbi, S. S., Pike, V. W., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.04.011 · Cited by 174
Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study
Schuitemaker, A., Kropholler, M. A., Boellaard, R., van der Flier, W. M., Kloet, R. W., van der Doef, T. F., Knol, D. L., Windhorst, A. D., Luurtsema, G., Barkhof, F., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.04.021 · Cited by 171 · cited 1×
“Nevertheless, some studies provided contradictory results [109,111,112].”
Rissanen, E., Tuisku, J., Rokka, J., Paavilainen, T., Parkkola, R., Rinne, J. O., & Airas, L. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.131698 · Cited by 171
Kenk, M., Selvanathan, T., Rao, N., Suridjan, I., Rusjan, P., Remington, G., Meyer, J. H., Wilson, A. A., Houle, S., & Mizrahi, R. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu157 · Cited by 169
Coughlin, J. M., Wang, Y., Ambinder, E. B., Ward, R. E., Minn, I., Vranesic, M., Kim, P. K., Ford, C. N., Higgs, C., Hayes, L. N., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.40 · Cited by 169
Glatiramer acetate: Mechanisms of action in multiple sclerosis
Schrempf, W., & Ziemssen, T. (2007) · Autoimmunity Reviews · doi:10.1016/j.autrev.2007.02.003 · Cited by 168
Wiley, C. A., Lopresti, B. J., Venneti, S., Price, J., Klunk, W. E., DeKosky, S. T., & Mathis, C. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.511 · Cited by 163 · cited 1×
“Nevertheless, some studies provided contradictory results [109,111,112].”
Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET
Ossenkoppele, R., Tolboom, N., Foster-Dingley, J. C., Adriaanse, S. F., Boellaard, R., Yaqub, M., Windhorst, A. D., Barkhof, F., Lammertsma, A. A., Scheltens, P., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2102-3 · Cited by 160
Zhang, Q.-S., Heng, Y., Yuan, Y.-H., & Chen, N.-H. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2016.11.002 · Cited by 156 · cited 1×
“Given the fact that a chronological spread of LB inclusions occurred in α-synucleinopathies [57], and these α-synuclein can directly provoke microglial activation [58], we could expect to find, in a time-dependent fashion, a widespread TSPO signal in PET imaging.”
BackgroundWilms, H., Claasen, J., Röhl, C., Sievers, J., Deuschl, G., & Lucius, R. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.07.002 · Cited by 154 · cited 1×
“Although modestly expressed in healthy brain parenchyma, TSPO is substantially upregulated predominantly in microglia cells in a number of neurodegenerative and neuroinflammatory diseases during the microglia activation process [16].”
BackgroundChew, L.-J., Fusar-Poli, P., & Schmitz, T. (2013) · Developmental Neuroscience · doi:10.1159/000346157 · Cited by 154 · cited 1×
“, soluble factors, cellular interactions [7,8]) induced morphological (i.”
BackgroundPolitis, M., Lahiri, N., Niccolini, F., Su, P., Wu, K., Giannetti, P., Scahill, R. I., Turkheimer, F. E., Tabrizi, S. J., & Piccini, P. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.011 · Cited by 153 · cited 1×
“We hypothesize that these genetics and thus clinical features could explain the difference in microglial activation, objectified by ventral striatum TSPO tracer binding variability in premanifest HD patients [88,89].”
BackgroundInfluence of l -dopa and pramipexole on striatal dopamine transporter in early PD
Guttman, M., Stewart, D. E., Hussey, D., Wilson, A., Houle, S., & Kish, S. J. (2001) · Neurology · doi:10.1212/wnl.56.11.1559 · Cited by 151
Yasuno, F., Kosaka, J., Ota, M., Higuchi, M., Ito, H., Fujimura, Y., Nozaki, S., Takahashi, S., Mizukami, K., Asada, T., et al. (2012) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2011.08.013 · Cited by 148 · cited 2×
“Analogous to Aβ and tau that has already accumulated in the brain of MCI patients [114], PET imaging showed that microglial activation occurred before the onset of clinical symptoms of dementia [108,110,115].”
BackgroundRojas, S., Martín, A., Arranz, M. J., Pareto, D., Purroy, J., Verdaguer, E., Llop, J., Gómez, V., Gispert, J. D., Milián, O., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600500 · Cited by 145 · cited 1×
“Thus, astrocytes were mainly observed in the rim surrounding the lesion core, whereas microglia were abundant in the core of infarction [19].”
BackgroundWidespread tau seeding activity at early Braak stages
Furman, J. L., Vaquer-Alicea, J., White, C. L., Cairns, N. J., Nelson, P. T., & Diamond, M. I. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1644-z · Cited by 145 · cited 1×
“A transcellular propagation of abnormal tau proteins [93] and Aβ [94] occurred in AD.”
BackgroundIn vivo imaging of microglial activation with [11C](R)‐PK11195 PET in corticobasal degeneration
Gerhard, A., Watts, J., Trender‐Gerhard, I., Turkheimer, F., Banati, R. B., Bhatia, K., & Brooks, D. J. (2004) · Movement Disorders · doi:10.1002/mds.20162 · Cited by 144 · cited 2×
“Elevated 11C-PK11195 binding in the striatum, thalamus and substantia nigra [64,65] is in consonance with neurological injury patterns in CBD [73,75], especially tau load [74].”
BackgroundColasanti, A., Guo, Q., Giannetti, P., Wall, M. B., Newbould, R. D., Bishop, C., Onega, M., Nicholas, R., Ciccarelli, O., Muraro, P. A., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.11.022 · Cited by 144
The role of tau in the pathological process and clinical expression of Huntington’s disease
Vuono, R., Winder-Rhodes, S., de Silva, R., Cisbani, G., Drouin-Ouellet, J., REGISTRY Investigators of the European Huntington’s Disease Network, Spillantini, M. G., Cicchetti, F., & Barker, R. A. (2015) · Brain · doi:10.1093/brain/awv107 · Cited by 139
PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET
Venneti, S., Lopresti, B. J., Wang, G., Hamilton, R. L., Mathis, C. A., Klunk, W. E., Apte, U. M., & Wiley, C. A. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.11.005 · Cited by 138 · cited 1×
“[34] observed that astrocytes are not a negligible factor in the increased TSPO PET radioligand binding.”
BackgroundFan, Z., Okello, A. A., Brooks, D. J., & Edison, P. (2015) · Brain · doi:10.1093/brain/awv288 · Cited by 135 · cited 2×
“Longitudinal studies exhibited an increase in cortical-activated microglia during the course of AD [101,103,110].”
BackgroundMaeda, J., Higuchi, M., Inaji, M., Ji, B., Haneda, E., Okauchi, T., Zhang, M.-R., Suzuki, K., & Suhara, T. (2007) · Brain Research · doi:10.1016/j.brainres.2007.04.054 · Cited by 133 · cited 1×
“Moreover, TSPO overexpression in both astrocytes and microglia seems to be temporally distinct depending on the stage of disease and the disease itself [35].”
BackgroundTerada, T., Yokokura, M., Yoshikawa, E., Futatsubashi, M., Kono, S., Konishi, T., Miyajima, H., Hashizume, T., & Ouchi, Y. (2016) · Annals of Nuclear Medicine · doi:10.1007/s12149-016-1099-2 · Cited by 133 · cited 3×
“In ROI analysis, extrastriatal 11C-DPA713 BPND remains stable Terada et al. (2016) [55] PD-RCT 24 PD patients: 18 with AZD3241 vs. 6 withplacebo 11C-PBR28 Compared to baseline, significantly reduced VT in nigrostriatal pathway, cortical regions, thalamus and cerebellum after 4 and 8 weeks of…”
BackgroundMethodAstrogliopathy predominates the earliest stage of corticobasal degeneration pathology
Ling, H., Kovacs, G. G., Vonsattel, J. P. G., Davey, K., Mok, K. Y., Hardy, J., Morris, H. R., Warner, T. T., Holton, J. L., & Revesz, T. (2016) · Brain · doi:10.1093/brain/aww256 · Cited by 133 · cited 2×
“In CBD, a recent report supports that astrogliopathy precedes neuronal loss, which leads to clinical symptoms as well as asymmetrical akinetic-rigidity, apraxia, disequilibrium and limb dystonia [74].”
BackgroundFrontotemporal Lobar Degeneration: Epidemiology, Pathology, Diagnosis and Management
Seltman, R. E., & Matthews, B. R. (2012) · CNS Drugs · doi:10.2165/11640070-000000000-00000 · Cited by 132
The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease
Schapansky, J., Nardozzi, J. D., & LaVoie, M. J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.049 · Cited by 132
Suridjan, I., Pollock, B. G., Verhoeff, N. P. L. G., Voineskos, A. N., Chow, T., Rusjan, P. M., Lobaugh, N. J., Houle, S., Mulsant, B. H., & Mizrahi, R. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.1 · Cited by 132 · cited 2×
“, prefrontal [104,107,108], temporal [100–102,104–109,125], occipital [101,104,105,107,108,125], precuneus [101,109,110], cingulum [100,104,110]) in AD dementia patients, compared to healthy subjects.”
BackgroundHu, X., Liou, A. K. F., Leak, R. K., Xu, M., An, C., Suenaga, J., Shi, Y., Gao, Y., Zheng, P., & Chen, J. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.06.002 · Cited by 131
Byrne, S., Heverin, M., Elamin, M., Bede, P., Lynch, C., Kenna, K., MacLaughlin, R., Walsh, C., Al Chalabi, A., & Hardiman, O. (2013) · Annals of Neurology · doi:10.1002/ana.23969 · Cited by 130
Fu, X., Zunich, S. M., O'Connor, J. C., Kavelaars, A., Dantzer, R., & Kelley, K. W. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-43 · Cited by 130
Harrison, N. A., Cooper, E., Dowell, N. G., Keramida, G., Voon, V., Critchley, H. D., & Cercignani, M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.09.023 · Cited by 129
Dolle, F., Luus, C., Reynolds, A., & Kassiou, M. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788803150 · Cited by 129
Dulamea, A. O. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-47861-6_7 · Cited by 128
Versijpt, J., Debruyne, J. C., Van Laere, K. J., De Vos, F., Keppens, J., Strijckmans, K., Achten, E., Slegers, G., Dierckx, R. A., Korf, J., et al. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1140oa · Cited by 126
Golla, S. S., Boellaard, R., Oikonen, V., Hoffmann, A., van Berckel, B. N., Windhorst, A. D., Virta, J., Haaparanta-Solin, M., Luoto, P., Savisto, N., et al. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.261 · Cited by 125
Grundman, M., Pontecorvo, M. J., Salloway, S. P., Doraiswamy, P. M., Fleisher, A. S., Sadowsky, C. H., Nair, A. K., Siderowf, A., Lu, M., Arora, A. K., et al. (2013) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318279d02a · Cited by 121
Translocator Protein PET Imaging for Glial Activation in Multiple Sclerosis
Oh, U., Fujita, M., Ikonomidou, V. N., Evangelou, I. E., Matsuura, E., Harberts, E., Ohayon, J., Pike, V. W., Zhang, Y., Zoghbi, S. S., et al. (2011) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-010-9243-6 · Cited by 118
Fan, Z., Calsolaro, V., Atkinson, R. A., Femminella, G. D., Waldman, A., Buckley, C., Trigg, W., Brooks, D. J., Hinz, R., & Edison, P. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.169078 · Cited by 118 · cited 1×
“These rs6971-insensitive radioligands, called third generation TSPO tracers, include 11C-ER176 [41] and flutriciclamide (18F-GE180) [42].”
BackgroundTranslocator Protein 18 kDa (TSPO): An Old Protein with New Functions?
Li, F., Liu, J., Liu, N., Kuhn, L. A., Garavito, R. M., & Ferguson-Miller, S. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00142 · Cited by 112 · cited 1×
“Others authors suggest a role of TSPO in oxidative stress by directly facilitating the breakdown of porphyrin [28].”
BackgroundMelah, K. E., Lu, S. Y.-F., Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150897 · Cited by 111 · cited 1×
“These results are consistent with the presence of neuroinflammatory biomarkers in the cerebrospinal fluid of pre-symptomatic AD subjects [116].”
ResultDean, B., Gibbons, A. S., Tawadros, N., Brooks, L., Everall, I., & Scarr, E. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.95 · Cited by 110
Aβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110 · cited 1×
“Analogous to Aβ and tau that has already accumulated in the brain of MCI patients [114], PET imaging showed that microglial activation occurred before the onset of clinical symptoms of dementia [108,110,115].”
BackgroundIncreased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome
Giannetti, P., Politis, M., Su, P., Turkheimer, F. E., Malik, O., Keihaninejad, S., Wu, K., Waldman, A., Reynolds, R., Nicholas, R., et al. (2015) · Brain · doi:10.1093/brain/awu331 · Cited by 106
Animal Models of MS Reveal Multiple Roles of Microglia in Disease Pathogenesis
Gao, Z., & Tsirka, S. E. (2011) · Neurology Research International · doi:10.1155/2011/383087 · Cited by 103
Liu, Z., Pardini, M., Yaldizli, Ö., Sethi, V., Muhlert, N., Wheeler‐Kingshott, C. A. M. G., Samson, R. S., Miller, D. H., & Chard, D. (2015) · Brain · doi:10.1093/brain/awv065 · Cited by 103
Veiga, S., Azcoitia, I., & Garcia-Segura, L. M. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20430 · Cited by 101 · cited 1×
“, kainic acid excitoxicity [29] or intracerebroventricular infusion of lipopolysaccharide (LPS) [30]) highlighted TSPO’s involvement in hippocampal gliosis and especially in microgliosis.”
BackgroundPark, E., Gallezot, J., Delgadillo, A., Liu, S., Planeta, B. M., Lin, S.-F., O’Connor, K. C., Lim, K., Lee, J., Chastre, A., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3043-4 · Cited by 101
In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with18F-PBR111 PET
Colasanti, A., Guo, Q., Muhlert, N., Giannetti, P., Onega, M., Newbould, R. D., Ciccarelli, O., Rison, S., Thomas, C., Nicholas, R., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.135129 · Cited by 100
Imaging Striatal Microglial Activation in Patients with Parkinson’s Disease
Koshimori, Y., Ko, J.-H., Mizrahi, R., Rusjan, P., Mabrouk, R., Jacobs, M. F., Christopher, L., Hamani, C., Lang, A. E., Wilson, A. A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138721 · Cited by 100 · cited 1×
“…regions Edison et al. (2013) [52] 19 PD patients vs. 17 HC 18F-FEPPA No significant difference in striatal VT values between PD patients and controls Koshimori et al. (2015) [50] - 11 PD patients without dementia vs. 12 HC - 11 PD patients were rescanned after 1 year 11C-DPA713 - Significantly…”
BackgroundNeuropathology of Parkinson’s Disease and Related Syndromes
Gibb, W. R. G. (1992) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30215-9 · Cited by 99 · cited 1×
“PD is neuropathologically characterized by a neuronal rarefaction in the substantia nigra pars compacta and the presence of neuronal Lewy bodies (LB) inclusions, which are abnormal aggregates of α-synuclein [47].”
BackgroundHaarman, B. C. M., Burger, H., Doorduin, J., Renken, R. J., Sibeijn‐Kuiper, A., Marsman, J.-B. C., de Vries, E. F. J., de Groot, J. C., Drexhage, H. A., Mendes, R., et al. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.09.004 · Cited by 97
The Translocator Protein (18 kDa): Central Nervous System Disease and Drug Design
Scarf, A. M., Ittner, L. M., & Kassiou, M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8011678 · Cited by 96
Cytokine expression and microglial activation in progressive supranuclear palsy
Fernández-Botrán, R., Ahmed, Z., Crespo, F. A., Gatenbee, C., Gonzalez, J., Dickson, D. W., & Litvan, I. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.06.007 · Cited by 93 · cited 1×
“[72] specified that the high degree of correlation between microglial activation, tau burden and the areas of degeneration (substantia nigra and subthalamic nucleus) previously described [73], involves a high expression level of IL-1β.”
BackgroundShukuri, M., Takashima-Hirano, M., Tokuda, K., Takashima, T., Matsumura, K., Inoue, O., Doi, H., Suzuki, M., Watanabe, Y., & Onoe, H. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.084046 · Cited by 93
Decreased microglial activation in MS patients treated with glatiramer acetate
Ratchford, J. N., Endres, C. J., Hammoud, D. A., Pomper, M. G., Shiee, N., McGready, J., Pham, D. L., & Calabresi, P. A. (2012) · Journal of Neurology · doi:10.1007/s00415-011-6337-x · Cited by 91
Varrone, A., Mattsson, P., Forsberg, A., Takano, A., Nag, S., Gulyás, B. Z., Borg, J., Boellaard, R., Al‐Tawil, N. G., Eriksdotter, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2359-1 · Cited by 90
Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease
Meßmer, K., & Reynolds, G. P. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00967-1 · Cited by 89 · cited 2×
“The colocalization of TSPO upregulation and activated glia has been observed in human degenerative disorders including AD, PD, multiple sclerosis (MS), (HD) [31] and amyotrophic lateral sclerosis (ALS) [32].”
BackgroundLisi, L., Stigliano, E., Lauriola, L., Navarra, P., & Russo, C. D. (2014) · ASN Neuro · doi:10.1042/an20130045 · Cited by 89 · cited 1×
“M2b cells are induced by the immune complex, secrete IL-10 and regulate the immune response [10].”
BackgroundClinical, MRI, and CSF Markers of Disability Progression in Multiple Sclerosis
Gajofatto, A., Calabrese, M., Benedetti, M. D., & Monaco, S. (2013) · Disease Markers · doi:10.1155/2013/484959 · Cited by 88
Femminella, G. D., Ninan, S., Atkinson, R., Fan, Z., Brooks, D. J., & Edison, P. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150827 · Cited by 88
Cited by
Microglial signatures and their role in health and disease
Butovsky, O., & Weiner, H. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0057-5 · Cited by 1,046
Global brain inflammation in stroke
Shi, K., Tian, D.-C., Li, Z.-G., Ducruet, A. F., Lawton, M. T., & Shi, F.-D. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30078-x · Cited by 911
La Joie, R., Visani, A. V., Baker, S. L., Brown, J. A., Bourakova, V., Cha, J., Chaudhary, K., Edwards, L., Iaccarino, L., Janabi, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5732 · Cited by 612
Microglia Mediated Neuroinflammation in Parkinson’s Disease
Isik, S., Yeman Kiyak, B., Akbayir, R., Seyhali, R., & Arpaci, T. (2023) · Cells · doi:10.3390/cells12071012 · Cited by 379
Microglia in multiple sclerosis: Friend or foe
Guerrero, B. L., & Sicotte, N. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00374 · Cited by 215
“Translocator Protein (TSPO) is located in the outer mitochondrial membrane and is upregulated in activated microglia (46, 47).”
BackgroundInfluential
Metadata
- Authors
- Dupont, A.-C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., & Arlicot, N.
- Affiliations
- Inserm (FR)
- Centre Hospitalier Universitaire de Tours (FR)
- CHRU Tours, 2 Boulevard Tonnellé, 37044 Tours, France
- Corresponding author
- Dupont, Anne-Claire
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-04-07
- Volume
- 18
- Issue
- 4
- Pages
- 785
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5412369
- OpenAlex
- W2605220880
- Cited by
- 182
- References
- 249
- Citations by year
- 2026: 16 · 2025: 14 · 2024: 10 · 2023: 12 · 2022: 14 · 2021: 13 · 2020: 34 · 2019: 31 · 2018: 25 · 2017: 13
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Funders
- Agence Nationale de la Recherche (ANR-11-LABX-0018)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- translocator protein (TSPO), TSPO PET imaging, microglial activation, neuroinflammation, neurodegenerative diseases, Parkinson's disease, Huntington's disease, dementia, amyotrophic lateral sclerosis, multiple sclerosis, mental illness, molecular biomarkers, radiopharmaceuticals, multiplexed imaging, cytokines, metabolomics
- MeSH terms
- Humans, Biomarkers, Up-Regulation, Microglia, Receptors, GABA, Radiopharmaceuticals, Neurodegenerative Diseases, Early Diagnosis, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.